[go: up one dir, main page]

MX2008010879A - Composiciones farmaceuticas de sodio de fluvastatina. - Google Patents

Composiciones farmaceuticas de sodio de fluvastatina.

Info

Publication number
MX2008010879A
MX2008010879A MX2008010879A MX2008010879A MX2008010879A MX 2008010879 A MX2008010879 A MX 2008010879A MX 2008010879 A MX2008010879 A MX 2008010879A MX 2008010879 A MX2008010879 A MX 2008010879A MX 2008010879 A MX2008010879 A MX 2008010879A
Authority
MX
Mexico
Prior art keywords
fluvastatin
fluvastatin sodium
stable
composition
pharmaceutical compositions
Prior art date
Application number
MX2008010879A
Other languages
English (en)
Inventor
Simona Di Capua
Yael Rotbart Cohen
Nava Shterman
Rina Zilberman
Ronit Yafeh
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2008010879A publication Critical patent/MX2008010879A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen diversas composiciones de fluvastatina y métodos para prepararlas. Un ejemplo es una composición farmacéutica de liberación controlada que comprende fluvastatina y por lo menos un polímero hidrófilo no iónico, en donde la composición está sustancialmente libre de hidroxipropil metilcelulosa. Otro ejemplo es una composición farmacéutica estable que comprende fluvastatina, preferentemente sodio de fluvastatina en donde la composición está sustancialmente libre de un agente de estabilización de alcalinización. Otro ejemplo es una formulación farmacéutica de liberación controlada estable, que comprende fluvastatina, preferentemente sodio de fluvastatina, que es estable con un contenido de agua superior al 3,5 por ciento en peso.
MX2008010879A 2006-02-24 2007-02-23 Composiciones farmaceuticas de sodio de fluvastatina. MX2008010879A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77652606P 2006-02-24 2006-02-24
PCT/US2007/005076 WO2007100822A2 (en) 2006-02-24 2007-02-23 Fluvastatin sodium pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2008010879A true MX2008010879A (es) 2008-10-27

Family

ID=38038960

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008010879A MX2008010879A (es) 2006-02-24 2007-02-23 Composiciones farmaceuticas de sodio de fluvastatina.

Country Status (11)

Country Link
US (1) US20080033030A1 (es)
EP (1) EP1825847A3 (es)
JP (1) JP2009527577A (es)
KR (1) KR20080094837A (es)
CN (1) CN101426478A (es)
BR (1) BRPI0708191A2 (es)
CA (1) CA2642195A1 (es)
IL (1) IL193358A0 (es)
MX (1) MX2008010879A (es)
RU (1) RU2008136767A (es)
WO (1) WO2007100822A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1928425E (pt) * 2006-05-12 2013-04-11 Pharmathen Sa Formulação farmacêutica contendo um inibidor de hmg-coa redutase e método para a preparação deste
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
FR2938433B1 (fr) * 2008-11-19 2011-09-09 Francois Fauran Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
CN102309452B (zh) * 2011-09-14 2013-01-23 海南美大制药有限公司 氟伐他汀钠脂质体固体制剂
CN102805739B (zh) * 2012-04-10 2013-08-14 宋芸 氟伐他汀钠缓释包衣滴丸及其制备方法
US10376470B2 (en) * 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
RU2591079C2 (ru) * 2014-12-10 2016-07-10 Александр Владимирович Диковский Фармацевтическая композиция статинов с пребиотиком для терапии гиперхолестеринемии и гиперлипидимии
CN119185228B (zh) * 2024-10-09 2025-08-01 杭州泓友医药科技有限公司 氟伐他汀钠缓释片及制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
GB9703388D0 (en) * 1997-02-18 1997-04-09 Sandoz Yakuhin K K Tokyo Sykk Organic compounds
CA2216215A1 (en) * 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6558659B2 (en) * 2000-04-10 2003-05-06 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
WO2001093860A1 (en) * 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6806290B2 (en) * 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
DE10316087A1 (de) * 2003-04-08 2004-11-11 Ratiopharm Gmbh Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen
JP3944494B2 (ja) * 2003-06-25 2007-07-11 ノバルティス アクチエンゲゼルシャフト フルバスタチン含有錠剤
ATE471713T1 (de) * 2003-06-25 2010-07-15 Novartis Pharma Gmbh Tablette enthaltend fluvastatin und calciumcarmellose
US6890941B1 (en) * 2003-12-03 2005-05-10 Procaps S.A. Compositions containing HMG Co-A reductase inhibitors and policosanol
WO2005058310A2 (en) * 2003-12-16 2005-06-30 Novartis Ag Use of stating for the treatment of metabolic syndrome
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
WO2005115380A2 (en) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
WO2006037348A1 (en) * 2004-10-01 2006-04-13 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and a statin
WO2006105806A1 (en) * 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
AR057422A1 (es) * 2005-06-29 2007-12-05 Panacea Biotec Ltd Uan composicion farmaceutica de liberacion modificada, proceso de preparacion de dicha composicion y metodo para emplear la misma
EP1818050A1 (de) * 2006-02-10 2007-08-15 Stada Arzneimittel Ag Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor

Also Published As

Publication number Publication date
WO2007100822A2 (en) 2007-09-07
CA2642195A1 (en) 2007-09-07
US20080033030A1 (en) 2008-02-07
EP1825847A2 (en) 2007-08-29
BRPI0708191A2 (pt) 2012-05-29
CN101426478A (zh) 2009-05-06
JP2009527577A (ja) 2009-07-30
EP1825847A3 (en) 2008-01-23
IL193358A0 (en) 2009-05-04
RU2008136767A (ru) 2010-03-27
KR20080094837A (ko) 2008-10-24
WO2007100822A3 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
MX2008010879A (es) Composiciones farmaceuticas de sodio de fluvastatina.
WO2007048219A3 (en) Sustained drug release composition
MY157790A (en) Trazodone composition for once a day administration
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
MX2010003923A (es) Formulacion farmaceutica de valsartan.
SG165314A1 (en) Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
PE20061449A1 (es) Composiciones farmaceuticas comprendiendo imatinib y un retardador de liberacion
PE20100265A1 (es) Nuevas composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion
TW200608975A (en) Pharmaceutical compositions
MY160703A (en) Crystalline forms of (r) -5- [3-chloro-4-(2,3-dihydroxy) - benz [z] ylidene] -2- ([z]-propylimino) -3-0-tolyl-thiazolidin-4-one
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
BRPI0821616B8 (pt) composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma
AR080242A1 (es) Composiciones veterinarias. usos.
NZ708247A (en) Hyaluronic acid based formulations
AU2009215514A9 (en) Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
NZ585219A (en) Fast release solid formulation, preparation and use thereof
CL2009000573A1 (es) Composicion farmaceutica inyectable intraocular en forma de suspension acuosa que no contiene preservante, que consiste de acetonido de triamcinolona, carboximetilcelulosa de sodio, 0,002-0,02% de polisorbato 80, cloruros para ajustar la tonicidad, agente tamponante, agua y agente de ajuste de ph; uso para tratar el ojo.
SG196810A1 (en) Controlled release pharmaceutical or foodformulation and process for its preparation
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением
EA201070806A1 (ru) Состав медленного высвобождения на основе ассоциации гликогена и альгината
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
MX2010006216A (es) Nuevos compuestos iii.
BRPI0606373A2 (pt) composição de xarope compreendendo dexibuprofeno como ingrediente ativo e método para a preparação da mesma
WO2008022745A8 (de) Formulierungen zur kontrollierten freisetzung agrochemischer wirkstoffe